Medications and Supplements for Cardiovascular Risk Reduction: A Precision Approach
What are the best medications for reducing cardiovascular risk? The most effective medications for heart disease prevention target four primary drivers: ApoB-containing lipoproteins (Statins, PCSK9 inhibitors), Blood Pressure (ACE inhibitors, ARBs), Metabolic Health (GLP-1s, SGLT2 inhibitors), and Chronic Inflammation (Low-dose Colchicine). A precision medicine approach combines these tools with lifestyle changes to stabilize existing plaque and prevent new arterial damage.
What’s in this post?
Which Medications Best Lower ApoB and Plaque Risk? A look at the evidence for Statins, Ezetimibe, and PCSK9 inhibitors.
How Does Lowering Blood Pressure Reduce Vascular Aging? Why reducing mechanical stress is as important as lowering cholesterol.
How Do GLP-1s and Metabolic Meds Protect the Heart? Moving "upstream" to treat insulin resistance and obesity.
Can Anti-Inflammatory Meds Prevent Plaque Rupture? The role of low-dose colchicine in stabilizing vulnerable plaque.
Which Supplements Actually Support Cardiovascular Health? Separating the science from the marketing on Omega-3s, Fiber, and Vitamin D.
How Do We Personalize Your Prevention Plan? The Ikigai approach to matching treatment intensity to biological risk.
A smarter way to think about when—and why—we use them
This may be the least exciting topic in our entire cardiovascular series. It’s also where some of the biggest risk reduction actually happens. Medications and supplements don’t get the same attention as exercise, nutrition, or sleep. They’re not as intuitive. They’re not as empowering. And for many people, they feel like a last resort.
But they matter—often more than we’d like to admit. When used thoughtfully, medications can meaningfully reduce long-term risk. Not as a replacement for lifestyle, but as a layer of protection when biology and behavior aren’t enough. The goal isn’t to prescribe more. It’s to use the right tools, at the right time, for the right person.
Start with the driver of risk
Cardiovascular disease doesn’t come from a single cause. It develops from a combination of forces acting on the arteries over decades. Think of cardiovascular prevention as layering protection over time—each intervention targeting a different part of the process. Instead of organizing medications by category, it’s more useful to think about them based on the problem they’re solving.
Which Medications Best Lower ApoB and Plaque Risk?
At the center of cardiovascular disease is atherosclerosis—the gradual buildup of plaque in the arteries. As we established in Atherosclerosis Part 1: ApoB and the Drivers of Plaque, this process is driven by ApoB-containing lipoproteins. The more exposure over time, the higher the risk.
Medications in this category are designed to reduce that exposure. Statins (such as atorvastatin [Lipitor] and rosuvastatin [Crestor]) remain the foundation for many patients. They are well-studied, effective, and reduce cardiovascular events. Ezetimibe (Zetia) can be added to further lower ApoB by reducing cholesterol absorption.
PCSK9 inhibitors (such as evolocumab [Repatha] and alirocumab [Praluent]) offer a more potent option for patients who need significant reduction or who don’t tolerate statins. Research such as the FOURIER Trial has shown that these medications dramatically lower LDL-C and ApoB, leading to a significant reduction in heart attacks and strokes. Bempedoic acid (Nexletol) is a newer alternative that may be useful in select cases. We’re not treating a number on a lab panel—we’re reducing cumulative exposure to the particles that drive plaque formation.
How Does Lowering Blood Pressure Reduce Vascular Aging?
Blood pressure is often overlooked because it’s so common, but over time, elevated pressure creates constant mechanical stress on the arterial wall. Each heartbeat becomes slightly more damaging. This is one of the most consistent and modifiable drivers of vascular aging.
Medications like ACE inhibitors (such as lisinopril [Prinivil, Zestril]), ARBs (such as losartan [Cozaar] or valsartan [Diovan]), thiazide diuretics (such as hydrochlorothiazide), and calcium channel blockers (such as amlodipine [Norvasc]) help reduce that stress. Lowering blood pressure doesn’t just improve a number—it reduces the wear and tear that accelerates vascular aging and protects the endothelial glycocalyx.
How Do GLP-1s and Metabolic Meds Protect the Heart?
Insulin resistance is one of the most important—and most underappreciated—drivers of cardiovascular risk. As we explored in our Insights on Food as Medicine, this is where daily behaviors have an outsized impact.
Medications like GLP-1 receptor agonists (such as semaglutide [Ozempic, Wegovy] or tirzepatide [Mounjaro, Zepbound]) can improve insulin sensitivity, support weight loss, and reduce cardiovascular risk. The landmark SELECT Trial demonstrated that semaglutide reduced the risk of major adverse cardiovascular events by 20% in overweight or obese patients with established heart disease, even without diabetes..
SGLT2 inhibitors (such as empagliflozin [Jardiance]), while originally developed for diabetes, also offer profound cardiovascular and renal benefits. This is upstream medicine. When you improve metabolic health, you often improve everything downstream.
When is Aspirin Necessary for Preventing Blood Clots?
Atherosclerosis builds risk over time, but heart attacks and strokes occur when a plaque ruptures and a clot forms. That’s where antiplatelet therapy comes in. Aspirin (Bayer, Ecotrin) can reduce clotting risk, but it’s not for everyone. The benefit depends heavily on baseline risk and must be balanced against bleeding risk. Plaque creates vulnerability; clotting determines whether that vulnerability becomes an event.
Can Anti-Inflammatory Meds Prevent Plaque Rupture?
Inflammation influences how plaque behaves. As we discussed in Atherosclerosis Part 2: How Plaques Grow and Change, some plaques remain stable while others become inflamed and fragile.
There is growing evidence that targeting inflammation can reduce events. Medications like low-dose colchicine (Colcrys) work by calming inflammatory pathways. The LoDoCo2 Trial showed that low-dose colchicine significantly reduced the risk of cardiovascular events in patients with chronic coronary disease. While not first-line for everyone, it adds another layer of risk reduction for high-risk patients.
Which Supplements Actually Support Cardiovascular Health?
Supplements are appealing because they feel "natural," but their impact is often modest. Some can be helpful:
Fiber: Fiber supplementation, such as psyllium (Metamucil), can support lipid and metabolic health.
Omega-3s: Prescription formulations like icosapent ethyl (Vascepa) have been shown in the REDUCE-IT Trial to reduce cardiovascular events in high-risk populations. Over-the-counter fish oil has not consistently shown the same benefit.
Vitamin D: While deficiency should be corrected for overall resilience, randomized trials like the VITAL Study have not shown that Vitamin D supplementation reduces heart attacks or strokes.
Others, like Niacin, have not shown meaningful outcome benefits in modern trials, and Red yeast rice suffers from inconsistent dosing and quality control.
How we decide what to use: The Ikigai approach
There is no one-size-fits-all plan. We begin by understanding your baseline risk through labs, imaging, and clinical history. We match the intensity of treatment to the level of risk. Lifestyle remains the foundation—nutrition, movement, sleep, and recovery—and medications add leverage when biology and behavior aren't enough.
The goal is not to be on medications forever. The goal is to reduce your lifetime exposure to risk. Cardiovascular risk is built over decades, and small changes sustained over time matter. The best plan is the one that fits your biology and evolves as your goals change.
FAQ Section
Do I have to take a statin if my cholesterol is high? Not necessarily. The decision depends on your total ApoB count, your calcium score (CAC), and other risk factors like inflammation and blood pressure. We look at the "whole picture" before recommending medication.
Are GLP-1 meds only for weight loss? No. While they are effective for weight loss, they are now recognized as powerful cardiovascular protectors that improve insulin sensitivity and reduce inflammation in the heart and blood vessels.
Can supplements replace blood pressure medication? Generally, no. While magnesium or hibiscus tea may offer very modest reductions, they cannot match the precision and power of ACE inhibitors or ARBs in preventing the mechanical damage that leads to strokes and heart failure.
Ready to Audit Your Risk?
Schedule Your Cardiovascular Audit - Discover the precise biological signals your body is sending and build a data-driven plan for longevity.
